Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Research analysts at Leerink Partnrs issued their FY2025 earnings per share (EPS) estimates for shares of Tandem Diabetes Care in a note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Kratky expects that the medical device company will earn ($1.30) per share for the year. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's FY2027 earnings at ($0.01) EPS.
Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The business had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 57.33% and a negative net margin of 18.71%. Tandem Diabetes Care's quarterly revenue was up 22.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.65) EPS.
A number of other research firms have also recently issued reports on TNDM. Piper Sandler cut their price target on Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Mizuho assumed coverage on Tandem Diabetes Care in a research report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 target price for the company. Wall Street Zen lowered Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Saturday, June 21st. Citigroup reaffirmed a "sell" rating and set a $14.00 target price (down previously from $24.00) on shares of Tandem Diabetes Care in a report on Wednesday, July 9th. Finally, Robert W. Baird lowered their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research report on Thursday, May 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $32.71.
View Our Latest Analysis on TNDM
Tandem Diabetes Care Price Performance
NASDAQ:TNDM traded down $0.29 during mid-day trading on Wednesday, reaching $15.08. The stock had a trading volume of 345,308 shares, compared to its average volume of 1,497,125. The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81. The stock has a market capitalization of $1.00 billion, a PE ratio of -5.43 and a beta of 1.48. Tandem Diabetes Care has a 12 month low of $14.87 and a 12 month high of $47.60. The stock has a 50-day simple moving average of $19.78 and a two-hundred day simple moving average of $23.90.
Hedge Funds Weigh In On Tandem Diabetes Care
Several hedge funds have recently made changes to their positions in TNDM. AlphaQuest LLC grew its holdings in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares during the period. Assetmark Inc. increased its stake in Tandem Diabetes Care by 42.9% during the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock valued at $34,000 after purchasing an additional 525 shares in the last quarter. NBC Securities Inc. purchased a new position in Tandem Diabetes Care in the 1st quarter worth approximately $37,000. Jones Financial Companies Lllp lifted its holdings in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after purchasing an additional 748 shares in the last quarter. Finally, Brooklyn Investment Group boosted its holdings in shares of Tandem Diabetes Care by 417.8% during the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock valued at $65,000 after acquiring an additional 2,741 shares during the last quarter.
Tandem Diabetes Care Company Profile
(
Get Free Report)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Recommended Stories
Before you consider Tandem Diabetes Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.
While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
